ODN 2088

ODN 2088 is a potent TLR3, TLR7 and TLR9 inhibitor. ODN 2088 shows no cytotoxic. ODN 2088 inhibits the release of IFN-α and IL-6[1][2][3].

Signaling Pathways >> Immunology/Inflammation >> Toll-like Receptor (TLR)

Research Areas >> Inflammation/Immunology

ODN 2088 (0.01, 0.1, 1, 10 μM; 48 h) shows no cytotoxic for for human PBMCs[1]. ODN 2088 (0.01, 0.1, 1, 10 μM; 24 h) inhibits the release of IFN-α in CpG-ODN 2216 (3 μM) and TLR7-ligand RNA-ORN 22075 (5 μM) stimulated human PBMCs[1]. ODN 2088 (0.01, 0.1, 1, 10 μM; 48 h) hardly inhibits the IL-6 release stimulated with CpG-ODN 2006 (100 nM) but inhibits the IL-6 release stimulated with imiquimod (5 μg/ml) in human PBMCs[1]. ODN 2088 (0.1, 1, 10 μM; 24 h) hardly inhibits IL-6 release by B-cells stimulated with CpG-DNA 2006 (100 nM) but inhibits the IL-6 release by imiquimod (5 μg/ml) stimulated human B-cells[1]. ODN 2088 (1, 10 μM; 48 h) increases the expression of CD86 and HLA-DR in the absence of CpG-ODN 2006 or imiquimod in CD20+ B-cells[1]. ODN 2088 presumably impairs TLR9-induced signaling induces by CpG-ODNs by competitive binding to the C-terminal fragment of TLR9[1]. ODN 2088 (0.001, 0.01, 0.1, 1, 10 μM; 24 h) inhibits the TNF-α secretion in a dose-dependent manner in CpG-ODN 1826 (100 nM) stimulated BMDMs and shows weekly inhibits when stimulated by the TLR7-agonist imiquimod[3]. ODN 2088 (10 μM) stimulates B cells to proliferate[3]. Cell Cytotoxicity Assay[1] Cell Line: Human PBMCs Concentration: 0.01, 0.1, 1, 10 μM Incubation Time: 48 h Result: Showed no cytotoxic for for human PBMCs.

[1]. Römmler F, et al. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells. PLoS One. 2015 Feb 19;10(2):e0116703.

[2]. Duramad O, et al. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol. 2005 May 1;174(9):5193-200.

[3]. Römmler F, et al. Guanine modification of inhibitory oligonucleotides potentiates their suppressive function. J Immunol. 2013 Sep 15;191(6):3240-53.